Afuco™ Anti-S. aureus ClfA ADCC Recombinant Antibody (Tefibazumab), ADCC Enhanced (CAT#: AFC-TAB-029)
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibodyto Human S. aureus Tefibazumab (marketed under the brand name Aurexis) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in patient with cystic fibrosis and of methicillin-resistant S. aureus.
Specific Inquiry
Specifications
- Immunogen
- The details of the immunogen for this antibody are not available.
- Host Species
- Human
- Derivation
- Humanized (from mouse)
- Type
- ADCC enhanced antibody
- Specificity
- Tested positive against native S. aureus antigen.
- Species Reactivity
- S. aureus
- Clone
- Tefibazumab
- Applications
- IP, IF, FuncS, FC, Neut, ELISA
- Conjugate
- Unconjugated
- Trade name
- Aurexis
- Generic Name
- Tefibazumab
- Related Disease
- Staphylococcal infections
Product Property
- Purity
- >95% by SDS-PAGE
- Storage
- Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Target
- Alternative Names
- Tefibazumab; aurexis; 521079-87-8; INH-H2002; S. aureus; Staphylococcus aureus; ClfA protein; NC_002952.2
Related Resources
Please refer to Tefibazumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Tefibazumab.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Tefibazumab"
Anti-S. Aureus Recombinant Antibody (Tefibazumab)Recombinant monoclonal antibodyto Human S. aureus Tefibazumab (marketed under the brand name Aurexis) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in patient with cystic fibrosis and of methicillin-resistant S. aureus.
See other products for "S. aureus ClfA"
Single-domain Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| NAB-2210-sdAb | Recombinant Anti-S. aureus ClfA VHH Single Domain Antibody | WB, IP, ChiP, Neut, ELISA | Llama VHH |
Humanized Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-029 | Anti-S. Aureus Recombinant Antibody (Tefibazumab) | IP, IF, FuncS, FC, Neut, ELISA, ICC | IgG1 - kappa |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for AFC-TAB-029. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.